Dabrafenib

Small Molecules

MEK/ERK pathway inhibitor; Inhibits

B-RAF V600E

Catalog # 73072 73074

10 mg 50 mg



Scientists Helping Scientists™ | www.stemcell.com

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713 INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

Dabrafenib is a reversible, selective, and ATP-competitive inhibitor of B-RAF with higher potency towards V600E mutant B-RAF compared to wild-type B-RAF or C-RAF, with IC₅₀ values of 0.8, 3.2, and 5 nM, respectively (Laquerre et al.; Menzies et al.).

Molecular Name: Dabrafenib

Alternative Names: Dabarefenib; GSK 2118436

CAS Number: 1195765-45-7 Chemical Formula: $C_{23}H_{20}F_3N_5O_2S_2$ Molecular Weight: 519.6 g/mol Purity: \geq 98%

Chemical Name: N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-

benzenesulfonamide

Structure:

Properties

Physical Appearance: A crystalline solid

Storage: Product stable at -20°C as supplied. Protect from prolonged exposure to light.

Stable as supplied for 12 months from date of receipt.

Solubility: \cdot DMSO \leq 55 mM

· Absolute ethanol ≤ 2 mM

For example, to prepare a 10 mM stock solution in DMSO, resuspend 10 mg in 1.92 mL of DMSO.

Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application.

Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Small Molecules Dabrafenib



Published Applications

CANCER RESEARCH

- · Decreases ERK phosphorylation and inhibits cell proliferation in cells expressing the B-RAF mutation V600E. Prevents tumor growth in mouse xenograft models of B-RAF(V600E) human melanoma and colon cancer (Rheault et al.). DISEASE MODELING
- · Alleviates acetaminophen-induced liver injury through distinct nanomolar inhibition of receptor-interacting protein (RIP3) in mice (Li et al.).

References

Li J-X et al. (2014) The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis 5: e1278.

Menzies AM et al. (2012) Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 6: 391–405. Rheault TR et al. (2013) Discovery of dabrafenib: A selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors. ACS Med Chem Lett 4(3): 358–62.

Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, visit www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

This product is hazardous. Please refer to the Safety Data Sheet (SDS).

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2021 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.